NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $5.02M rose 30.5% year over year, ahead of the +2.8% change in trailing-twelve-month operating expenses. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at -27.4% a year.
Context
- Operating expenses amounted to 1383.2% of revenue in FY2025.
- Operating expenses increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +30.5% holds above the trailing-twelve-month pace of +2.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 16.94M USD
- Year-over-year change
- -14.0%
- 4-year CAGR
- -35.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.94M | -14.0% |
| FY2024 | 2024-12-31 | 19.7M | -28.6% |
| FY2023 | 2023-12-31 | 27.58M | -37.8% |
| FY2022 | 2022-12-31 | 44.33M | -53.4% |
| FY2021 | 2021-12-31 | 95.2M | — |
Operating Expenses vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 operating expenses of $18.04M is the 8th highest of the 9 companies compared; the peer median is $47.98M.
- Its year-over-year change of +2.8% is the 3rd highest of 9, against a peer median of -30.9%.
- Operating expenses amounts to 786.8% of revenue for NRXP, versus a peer median of 208.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $229.32M | -10.3% | -7.8% | 151.8% | |
| LTM Mar 2026 | $87.08M | -41.0% | -7.2% | — | |
| LTM Mar 2026 | $59.37M | -22.3% | +2.5% | 17821.9% | |
| LTM Mar 2026 | $52.24M | +6.3% | -0.3% | 159.6% | |
| LTM Jun 2026 | $43.72M | -39.4% | -5.5% | 208.2% | |
| LTM Mar 2026 | $34.01M | -44.2% | -8.3% | — | |
| LTM Mar 2026 | $20.3M | -54.6% | -32.8% | — | |
| LTM Mar 2026 | $18.04M | +2.8% | -27.4% | 786.8% | |
| LTM Mar 2026 | $14.13M | +26.1% | -25.3% | 999.7% | |
| Peer median (excluding NRXP) | $47.98M | -30.9% | -7.5% | 208.2% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Cost of Revenue | 2K | 4K | 5K | 5K | 505K |
| Gross Profit | (2K) | (4K) | (5K) | (5K) | 720K |
| Gross Margin | — | — | — | — | 58.8% |
| Research & Development | 20.26M | 17.03M | 13.37M | 6.2M | 3.78M |
| Selling, General & Admin | 74.94M | 27.3M | 14.21M | 13.5M | 13.06M |
| Operating Expenses | 95.2M | 44.33M | 27.58M | 19.7M | 16.94M |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| EBITDA | (93.04M) | (39.75M) | (30.03M) | (24.04M) | (27.81M) |
| EBITDA Margin | — | — | — | — | -2270.0% |
| Operating Income | (95.2M) | (44.34M) | (27.59M) | (19.7M) | (16.22M) |
| Operating Margin | — | — | — | — | -1324.4% |
| Interest Income | 18 | 249K | 494K | 44K | 12K |
| Interest Expense | 18K | 0 | 120K | 1.08M | 671K |
| Other Income / Expenses | 2.14M | 4.58M | (2.56M) | (5.42M) | (12.4M) |
| Income Before Tax | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Pre-Tax Margin | — | — | — | — | -2336.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Net Margin | — | — | — | — | -2336.5% |
| EPS (Basic) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| EPS (Diluted) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| Weighted Avg Shares | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
| Weighted Avg Shares (Diluted) | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.